Glucose metabolism and incretins level in morbidly obese patients and in patients after biliopancreatic diversion performed for morbid obesity

We’ve studied a carbohydrate metabolism in morbidly obese (MO) patients and the patients after bariatric surgery. The patients of the 1st group had BMI>40 (n=22) and no history of diabetes mellitus. Patients after biliopancreatic diversion (BPD) performed for MO were included in the 2nd group (n=23). The 3rd group was a control group of normal weight healthy subjects (n=22). Blood glucose levels, insulin, GLP-1, GIP and glucagon during the OGTT (with 75 g of glucose) at 0, 30, 60 and 120 minutes were measured in all patients. In MO group fasting glucose levels were the highest. Impaired glucose metabolism was revealed in 68.2% of patients (n=10). Impaired fasting glucose (IFG) was diagnosed in 4 cases (18.2%), impaired glucose tolerance (IGT) in 11 patients (50%). In the BPD postprandial blood glucose levels (120 min) were lower if compared to the other groups. In 4 individuals (17.4%) we found postprandial hypoglycemia (<2.8 mmol/l). Patients of the MO group had the highest fasting insulin levels and HOMA-IR (p<0.001). The maximum of insulin concentration was seen on minute 30 of the OGTT in the 2nd and 3rd groups, and it was significantly higher in the post-bariatric patients (p=0.026). In MO group the maximum of the plasma insulin levels were on the 60th minute and were still elevated after 120 minutes. Fasting and stimulated (on the 30th minute) levels of GLP-1 were significantly higher after BPD (р=0.037 and p=0.022 at 0 and 30 min, respectively). Morbidly obese patients had higher fasting and stimulated GIP. Fasting glucagon concentrations were similar in the surgical and control groups, while the people with MO had higher initial levels of glucagon (p=0.013) and it was not suppressed during the OGTT (p=0.076). Glucose intolerance and insulin resistance incidence was higher in MO patients. Hyperglucagonemia, increased GIP and decreased GLP-1 levels are observed in MO patients. Stimulated plasma insulin and GLP-1 concentrations were significantly increased in patients who underwent BPD, and may cause postprandial hypoglycemia.

biliopancreatic diversion, obesity, GLP-1, GIP, glucagon, hypoglycemia

1. Anjana R, Pradeepa R, Deepa M еt al. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: Phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia. 2011; 54(12): 3022-7.

2. Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009; 122(3): 248-56.

3. Campos G, Rabl C, Peeva S et al. Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg. 2010; 14: 15-23.

4. Carr R, Larsen M, Jelic K et al. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab. 2010; 95(2): 872-8.

5. Cosson E, Hamo-Tchatchouang E, Banu I et al. A large proportion of prediabetes and diabetes goes undiagnosed when only fasting plasma glucose and/orHbA1c are measured in overweight or obese patients. Diabetes Metab. 2010; 36(4): 312-8.

6. Cowie C, Rust K, Ford E et al. Full accounting of diabetes and pre-diabetes in the U.S. Population in 1988-1994 and 2005-2006. Diabetes Care. 2009; 32: 287-94.

7. Cummings D, Overduin J, Foster-Schubert K et al. Role of the bypassed proximal intestine in the antidiabetic effects of bariatric surgery. Surg Obes Relat Dis. 2007; 3: 109-115.

8. Diabetes atlas. 4th edition. Brussels (Belgium): International Diabetes Federation; 2009. Available at: http://www.diabetesatlas.org/. Accessed October 9, 2010.

9. Dixon J, O’Brien P, Playfair J et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008; 299: 316-23.

10. Falkén Y, Hellstrom P, Holst J et al. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab. 2011; 96: 2227-35.

11. Ferrannini E, Muscelli E, Natali A et al. Association of fasting glucagon and proinsulin concentrations with insulin resistance. Diabetologia. 2007; 50: 2342-7.

12. Freedman D, Ron E, Ballard-Barbash R et al. Body mass index and all-cause mortality in a nationwide US cohort. Int J Obes (Lond). 2006; 30: 822-9.

13. Goldfine A, Mun E, Devine E et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab. 2007; 92: 4678-85.

14. Guh D, Zhang W, Bansback N et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 9: 88.

15. Hofsø D, Jenssen T, Hager H et al. Fasting plasma glucose in the screening for type 2 diabetes in morbidly obese subjects. Obes Surg. 2010; 20(3): 302-7.

16. Isbell J, Tamboli R, Hansen E et al. The importance of caloric restriction in the early improvements in insulin sensitivityafter Roux-en-Y gastric bypass surgery. Diabetes Care. 2010; 33: 1438-42.

17. Jankovic D, Wolf P, Anderwald C et al. Prevalence of endocrine disorders in morbidly obese patients and the effect of bariatric surgery on endocrine and metabolic parameters. Obes Surg. 2012; 22(1): 62-9.

18. Kanell W, D'Agostino R, Cobb J. Effect of weight on cardiovascular disease. American Journal of Clinical Nutrition 1996, 63(Suppl), 419S-22S.

19. Kashyap S, Daud S, Kelly K et al. Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell func-tion and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes (Lond). 2010; 34: 462-71.

20. Kim W, Egan J. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008; 60: 470-512.

21. Knop F, Aaboe K, Vilsbøll T. et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab. 2012;14(6): 500-10.

22. Korner J, Bessler M, Inabnet W. et al. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis. 2007; 3: 597-601.

23. Laferrere B, Heshka S, Wang K. et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007; 30: 1709-16.

24. Laferrere B, Teixeira J, McGinty J. et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008; 93: 2479-85.

25. Lenz M, Richter T, Muhlhauser I. The morbidity and mortality associated with overweight and obesity in adulthood: a systematic review. Dtsch Arztebl Int. 2009; 106 (40): 641-8.

26. Manson J, Willett W, Stamfer M. et al. Body weight and mortality among women. New England Journal of Medicine. 1995; 333: 677-85.

27. Murphy K, Dhillo W, Bloom S. Gut peptides in the regulation of food intake and energy homeostasis. Endocrine Reviews. 2006; 27(7): 719-27.

28. Muscelli E, Mari A, Casolaro A. et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes. 2008; 57: 1340-8.

29. Neary M, Batterham R. Gut hormones: implications for the treatment of obesity. Pharmacology & Therapeutics. 2009; 124: 44-56.

30. Patti M, McMahon G, Mun E. et al. Severe hypoglycaemia postgastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia. 2005; 48: 2236-40.

31. Promintzer-Schifferl M, Prager G, Anderwald C. et al. Effects of gastric bypass surgery on insulin resistance and insulin secretion in nondiabetic obese patients. Obesity (Silver Spring). 2011; 19: 1420-6

32. Rask E, Olsson T, Soderberg S. et al. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism. 2004; 53: 624 -31.

33. Reed M, Pories W, Chapman W. et al. Roux-en-Y gastric bypass corrects hyperinsulinemia implications for the remission of type 2 diabetes. J Clin Endocrinol Metab. 2011; 96: 2525-31.

34. Rubino F, Gagner M, Gentileschi P. et al. The early effect of Roux-en-Y gastric bypass on hormones is involved in body weight regulation and glucose metabolism. Ann Surg. 2004; 240: 236-42.

35. Rudnicki M, Patel D, McFadden D. et al. Proximal jejunal and biliary effects on the enteroinsular axis. Surgery. 1990; 107: 455-60.

36. Satman I, Omer B, Tutuncu Y et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol. 2013; 28: 169-80.

37. Scavini M, Pontiroli A, Folli F. Asymptomatic hyperinsulinemic hypoglycemia after gastric banding. N Engl J Med. 2005; 353: 2822-3.

38. Schinner S, Kempf K, Overmann H et al. Association of impaired glucose metabolism in morbid obesity with hypoadiponectinaemia. Exp Clin Endocrinol Diabetes. 2008: 116(Suppl 1): S64-9.

39. Service G, Thompson G, Service F et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med. 2005; 353: 249-54.

40. Shaper A, Wannamethee S, Walker M. Body weight: implications for the prevention of coronary heart disease, stroke, and diabetes mellitus in a cohort study of middle aged men. British Medical Journal. 1997; 314: 1311-7.

41. Swarbrick M, Stanhope K, Austrheim-Smith I et al. Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia. 2008; 51(10): 1901-11.

42. The DECODE study group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003; 26: 61-9.

43. Umeda L, Silva E, Carneiro G et al. Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients. Obes Surg. 2011; 21: 896-901.

44. Vazquez G, Duval S, Jacobs D et al. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta analysis. Epidemiol Rev. 2007; 29: 115-28.

45. Verdich C, Toubro S, Buemann B et al. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety - effect of obesity and weight reduction. Int J Obes Relat Metab Disord. 2001; 25: 1206-14.

46. Vidal J, Nicolau J, Romero F et al. Long-term effects of Roux-en-Y gastric bypass surgery on plasma glucagon-like peptide-1 and islet function in morbidly obese subjects. J Clin Endocrinol Metab. 2009; 94: 884-91.

47. Vilsbøll T, Krarup T, Sonne J et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003; 88: 2706-13.

48. Vinciguerra F, Baratta R, Farina M et al. Very severely obese patients have a high prevalence of type 2 diabetes mellitus and cardiovascular disease. Acta Diabetol. 2013; 50(3): 443-9.

49. World Health Organisation. Obesity: preventing and managing the global epidemic. 1997, Geneva:WHO.